Aquestive Therapeutics

Trial and FDA signals

• FDA complete response letter Received an FDA complete response letter (NDA 219870, letter dated Jan 30, 2026). FDA NDA 219870 (Jan 30, 2026)
  Evidence (1 event)

  • Jan 30, 2026 · FDA NDA 219870
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Aquestive Therapeutics Inc. Attention: Melina Cioffi, PharmD Vice President, Regulatory Affairs Warren, NJ (street omitted) Dear Dr. Cioffi: Please refer to your new drug ap

Job counts as of Oct 18, 2026. All trial and FDA signals